InMed announces annual general and special shareholder meeting
INM•InMed Pharmaceuticals will hold its annual general and special shareholder meeting on November 4, 2026. Shareholders will vote on a return-of-capital proposal involving contingent value rights tied to the proposed Mentari Therapeutics merger.
1. Meeting and proposal
InMed Pharmaceuticals will hold its annual general and special shareholder meeting on November 4, 2026. Shareholders will vote on a return-of-capital proposal covering contingent value rights tied to the proposed Mentari Therapeutics merger. If approved, holders of record on November 5, 2026, would receive one contingent value right per outstanding common share.
